Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

As Clostridium difficile creates a significant economic and morbidity burden for hospitals, researchers with Cleveland Clinic and the University of Texas School of Public Health in Houston sought to ...

Current guidelines recommend using either metronidazole or vancomycin to treat C. diff infections. “For many years the two antibiotics were considered to be equivalent in their ability to cure C. diff ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

Clostridiumdifficile infection (also known as C. diff or CDI) is one of the most common hospital-acquired infections and is a frequent cause of death among hospitalized older adults. Keystone ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

Vowst is a prescription drug that’s used in adults to help prevent Clostridioides difficile (C. diff) infection from coming back after it has been treated. Vowst comes as an oral capsule. Vowst ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

Fever, nausea, cramping, and diarrhea — if you have ulcerative colitis (UC), you probably know that those symptoms signal a flare. The same symptoms can also be a Clostridioides difficile (C. diff) ...

Testing for C. difficile is indicated in patients with diarrhea, especially after antibiotic use or healthcare exposure. Early testing facilitates prompt diagnosis and management, influencing ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...